Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | ALB | P02768 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | CCKBR | P32239 | 8/20 | 0.61 |
| ▸ | CCKAR | P32238 | 3/20 | 0.60 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL641962 | 0.88 | MEN1 (0.66) | CHRM1MEN1LMNAALBKMT2A | |
| SCHEMBL4819173 | 0.88 | MEN1 (0.69) | CHRM1MEN1LMNAALBKMT2A | |
| SCHEMBL643277 | 0.87 | CCKBR (0.68) | CCKBRCCKARBDKRB1 | |
| Cyclohexane SCHEMBL3971471 | 0.85 | MEN1 (0.65) | CHRM1MEN1LMNAALBKMT2A | |
| SCHEMBL6005237 | 0.85 | CCKBR (0.57) | CHRM1MEN1LMNAALBKMT2A | |
| SCHEMBL5418531 | 0.83 | LMNA (0.72) | CHRM1MEN1LMNAALBKMT2A | |
| SCHEMBL8672699 | 0.83 | CCKBR (0.62) | CHRM1MEN1LMNAALBKMT2A | |
| SCHEMBL643718 | 0.82 | CCKBR (0.62) | CHRM1MEN1LMNAALBKMT2A | |
| SCHEMBL5424738 | 0.81 | MEN1 (0.68) | CHRM1MEN1LMNAALBKMT2A | |
| SCHEMBL642028 | 0.81 | CCKBR (0.62) | CHRM1MEN1LMNAALBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853204-B2 | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the RSV fusion protein | ARROW THERAPEUTICS LIMITED (GB) | 2014-10-07 | — | — | US | claimed |
| JP-4719466-B2 | — | — | 2011-07-06 | — | — | JP | claimed |
| US-20100015063-A1 | Benzodiazepine Derivatives and Pharmaceutical Compositions Containing Them | ARROW THERAPEUTICS LIMITED (GB) | 2010-01-21 | — | — | US | claimed |
| EP-1727550-B1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND AN INHIBITOR OF THE RSV FUSION PROTEIN | ARROW THERAPEUTICS LTD (GB) | 2009-07-29 | — | — | EP | claimed |
| US-20070293482-A1 | Process for Preparing Benzodiazepines | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2007-12-20 | — | — | US | claimed |
| US-20070142403-A1 | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein | NOVARTIS PHARMACEUTICALA CORPORATION (US) | 2007-06-21 | — | — | US | claimed |
| EP-1727550-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND AN INHIBITOR OF THE RSV FUSION PROTEIN | Arrow Therapeutics Limited (GB) | 2006-12-06 | — | — | EP | claimed |
| US-20060040923-A1 | Benzodiazepine derivatives and pharmaceutical compositions containing them | ARROW THERAPEUTICS LIMITED (GB) | 2006-02-23 | — | — | US | claimed |
| JP-2006503054-A | — | — | 2006-01-26 | — | — | JP | claimed |
| WO-2005090319-A1 | PROCESS FOR PREPARING BENZODIAZEPINES | ARROW THERAPEUTICS LIMITED (GB) | 2005-09-29 | — | — | WO | claimed |
| WO-2005089769-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND AN INHIBIT OR OF THE RSV FUSION PROTEIN | ARROW THERAPEUTICS LIMITED (GB) | 2005-09-29 | — | — | WO | claimed |
| EP-1539716-A1 | BENZODIAZEPINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Arrow Therapeutics Limited (GB) | 2005-06-15 | — | — | EP | claimed |
| WO-2004026843-A1 | BENZODIAZEPINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ARROW THERAPEUTICS LIMITED (GB) | 2004-04-01 | — | — | WO | claimed |
| US-8853204-B2 | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the RSV fusion protein | ARROW THERAPEUTICS LIMITED (GB) | 2014-10-07 | — | — | US | disclosed |
| WO-2012081033-A2 | A PROCESS FOR PREPARATION OF IMIPENEM | SEQUENT SCIENTIFIC LIMITED (IN) | 2012-06-21 | — | — | WO | disclosed |
| US-8119630-B2 | Benzodiazepine derivatives and pharmaceutical compositions containing them | ARROW THERAPEUTICS LIMITED (GB) | 2012-02-21 | — | — | US | disclosed |
| WO-2005090319-A1 | PROCESS FOR PREPARING BENZODIAZEPINES | ARROW THERAPEUTICS LIMITED (GB) | 2005-09-29 | — | — | WO | disclosed |
| EP-1539716-A1 | BENZODIAZEPINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Arrow Therapeutics Limited (GB) | 2005-06-15 | — | — | EP | disclosed |
| US-20040220168-A1 | Process for the preparation of imipenem | RANBAXY LABORATORIES LIMITED (IN) | 2004-11-04 | — | — | US | disclosed |
| WO-2004026843-A1 | BENZODIAZEPINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ARROW THERAPEUTICS LIMITED (GB) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220168-A1 | Process for the preparation of imipenem | ITPA, MGAM, SI | CHRM1 3922/4885MEN1 2541/4885LMNA 1678/4885 |
| US-20060040923-A1 | Benzodiazepine derivatives and pharmaceutical compositions containing them | GABRA6, CNR1, SIGMAR1 | CHRM1 38/4885MEN1 4008/4885LMNA 1425/4885 |
| US-20070293482-A1 | Process for Preparing Benzodiazepines | CNR1, SIGMAR1, GABRA3 | CHRM1 31/4885MEN1 3084/4885LMNA 1532/4885 |
| US-20100015063-A1 | Benzodiazepine Derivatives and Pharmaceutical Compositions Containing Them | GABRA6, CNR1, SIGMAR1 | CHRM1 34/4885MEN1 3949/4885LMNA 1262/4885 |
| US-20070142403-A1 | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein | GABRP, TSPO, GABRA1 | CHRM1 2004/4885MEN1 4373/4885LMNA 1760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.